Randomized Trialhigh evidence
Eplontersen for Transthyretin Amyloid Cardiomyopathy.
The New England journal of medicine·August 28, 2026·PMID 42663301
Why it mattersATTR-CM is a progressive, life-threatening cardiomyopathy with limited disease-modifying options. This large, well-powered trial provides high-quality evidence on whether eplontersen, an antisense oligonucleotide that reduces transthyretin production, improves cardiovascular outcomes. The neutral result informs treatment decisions and highlights the need for alternative or combination strategies.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled